Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wade, D T
Right arrow Articles by Robson, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wade, D T
Right arrow Articles by Robson, P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 12, No. 5, 639-645 (2006)
DOI: 10.1177/1352458505070618

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

D T Wade

Oxford Centre for Enablement, Windmill Road, Oxford OX3-7LD, UK, derick.wade{at}noc.anglox.nhs.uk

P M Makela

Oxford Centre for Enablement, Windmill Road, Oxford OX3-7LD, UK

H House

Oxford Centre for Enablement, Windmill Road, Oxford OX3-7LD, UK

C Bateman

Oxford Centre for Enablement, Windmill Road, Oxford OX3-7LD, UK

P Robson

University Department of Psychiatry, Warneford Hospital, Warneford Lane, Oxford OX3-7JX, UK

The object of this study was to monitor the safety and efficacy of long-term use of an oromucosal cannabis-based medicine (CBM) in patients with multiple sclerosis (MS). A total of 137 MS patients with symptoms not controlled satisfactorily using standard drugs entered this open-label trial following a 10-week, placebo-controlled study. Patients were assessed every eight weeks using visual analogue scales and diary scores of main symptoms, and were followed for an average of 434 days (range: 21- 814). A total of 58 patients (42.3%) withdrew due to lack of efficacy (24); adverse events (17); withdrew consent (6); lost to follow-up (3); and other (8). Patients reported 292 unwanted effects, of which 251 (86%) were mild to moderate, including oral pain (28), dizziness (20), diarrhoea (17), nausea (15) and oromucosal disorder (12). Three patients had five ‘serious adverse events’ between them - two seizures, one fall, one aspiration pneumonia, one gastroenteritis. Four patients had first-ever seizures. The improvements recorded and dosage taken in the acute study remained stable. Planned, sudden interruption of CBM for two weeks in 25 patients (of 62 approached) did not cause a consistent withdrawal syndrome, although 11 (46%) patients reported at least one of - tiredness, interrupted sleep, hot and cold flushes, mood alteration, reduced appetite, emotional lability, intoxication or vivid dreams. Twenty-two (88%) patients re-started CBM treatment. We conclude that long-term use of an oromucosal CBM (Sativex) maintains its effect in those patients who perceive initial benefit. The precise nature and rate of risks with long-term use, especially epilepsy, will require larger and longer-term studies.

Key Words: cannabis • chronic use • multiple sclerosis • safety


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CMAJHome page
T. Wang MSc, J.-P. Collet PhD MD, S. Shapiro PhD, and M. A. Ware MBBS MSc
Adverse effects of medical cannabinoids: a systematic review
Can. Med. Assoc. J., June 17, 2008; 178(13): 1669 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Palazuelos, N. Davoust, B. Julien, E. Hatterer, T. Aguado, R. Mechoulam, C. Benito, J. Romero, A. Silva, M. Guzman, et al.
The CB2 Cannabinoid Receptor Controls Myeloid Progenitor Trafficking: INVOLVEMENT IN THE PATHOGENESIS OF AN ANIMAL MODEL OF MULTIPLE SCLEROSIS
J. Biol. Chem., May 9, 2008; 283(19): 13320 - 13329.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
P. Papathanasopoulos, L. Messinis, E. Lyros, A. Kastellakis, and G. Panagis
Multiple Sclerosis, Cannabinoids, and Cognition
J Neuropsychiatry Clin Neurosci, February 1, 2008; 20(1): 36 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A. Bowling
Cannabinoids in MS--are we any closer to knowing how best to use them?
Multiple Sclerosis, September 1, 2006; 12(5): 523 - 525.
[PDF]